Report data from adolescent cohort of PK run-in study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 May 2025
- Due
- 30 Sep 2025
- Delivered
- September 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Data in adolescent cohort of PK run-in study planned for Sept 2025”
What we found
Evidence strength A What the grades mean
The company completed the adolescent PK run-in study and reported that the pharmacokinetic and exposure data were similar to adults, fulfilling the commitment to report data by September 2025.
-
A Larimar Therapeutics, Inc. 10-K filed 2026-03-19
“We completed dosing in 14 adolescents in March 2025. The PK and exposure data were similar to adults and the participants became eligible to enroll in the OL study.” ✓ confirmed on the page
Market reaction: the shares moved +9.5% against the S&P 500 over the three sessions around the disclosure (18 Mar 2026 to 23 Mar 2026). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 5 May 2025
Deadline 30 Sep 2025 (“Sept 2025”) · wording expected
-
Version 2 · stated 23 Jun 2025
Deadline 30 Sep 2025 (“in September 2025”) · target 14 participants · wording expected
“Adolescent PK run-in data expected in September 2025 from 14 participants”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Adolescent cohort PK run-in study data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-LRMR-003045 · Corrections policy